HIV/HBV合并感染研究进展

摘要

The same routes of transmission of HIV and HBV increase the risk of HIV/HBV co-infection. Both kinds of the viruses interact by promoting each other's gene transcription and replication, so genetic recombination among them may produce ad-ditional mutations and affect the treatment effect. Some nucleos (t)ide analogues such as lamivudine, emtricitabine, entecavir and tenofovir, have both anti-HIV and anti-HBV activities, and it is likely to induce the emergence of resistant strains of HIV and/or HBV and cross resistance of the antiviral agents if they are not properly used, which may lead to serious effects on the prognosis of AIDS and chronic hepatitis B. This article reviews the research progress of HIV/HBV co-infection.%由于HIV和HBV具有相同的传播途径，增加了HIV/HBV合并感染的风险。二种病毒相互促进彼此基因的转录复制，可能发生基因重组而产生新的变异，影响治疗效果。抗HIV和HBV的药物中包含了相同的核苷（酸）类似物（如拉米夫定、恩曲他滨、恩替卡韦和替诺福韦酯），如果不能正确使用这些具有双重抗病毒活性的药物，就很可能诱导HIV或HBV耐药株的出现以及抗病毒药物之间的交叉耐药，对AIDS和慢性乙型肝炎的预后带来严重的影响。本文对HIV/HBV合并感染的研究进展进行综述。